INTERFERON BETA-1B
drugOn this page
Also known as BetaferonBetaseronExtavia
Summary
Interferon Beta-1B (CHEMBL1201563) is an approved protein (ATC L03AB08); indicated across 7 conditions including neoplasm and multiple sclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L03AB08
- Indications: 7 conditions
- Clinical trials: 18
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201563 |
| Name | INTERFERON BETA-1B |
| Type | Protein |
| Max phase | 4 |
| ATC | L03AB08 |
Also known as: Betaferon, Betaseron, Extavia, Interferon beta-1b, INTERFERON BETA-1B
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| multiple sclerosis | 4 | MONDO:0005301 | MONDO:0005301 |
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000764 |
| cardiomyopathy | 2 | MONDO:0004994 | EFO:0000318 |
| Orthocoronavirinae infectious disease | 2 | MONDO:0020753 | MONDO:0100116 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 7 |
| PHASE2 | 6 |
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00176592 | PHASE4 | COMPLETED | Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI |
| NCT00202995 | PHASE4 | TERMINATED | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS |
| NCT00206648 | PHASE4 | COMPLETED | An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS |
| NCT00317941 | PHASE4 | COMPLETED | Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif |
| NCT01144052 | PHASE4 | COMPLETED | Natalizumab De-escalation With Interferon Beta-1b |
| NCT01701856 | PHASE4 | TERMINATED | Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis |
| NCT03177083 | PHASE4 | COMPLETED | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy |
| NCT00002238 | PHASE3 | COMPLETED | Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen |
| NCT04276688 | PHASE2 | COMPLETED | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment |
| NCT04343768 | PHASE2 | COMPLETED | An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial |
| NCT04350281 | PHASE2 | COMPLETED | Double Therapy With IFN-beta 1b and Hydroxychloroquine |
| NCT04465695 | PHASE2 | UNKNOWN | Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 |
| NCT04494399 | PHASE2 | UNKNOWN | IFN Beta-1b and Ribavirin for Covid-19 |
| NCT04647695 | PHASE2 | UNKNOWN | IFN-beta 1b and Remdesivir for COVID19 |
| NCT00000695 | PHASE1 | COMPLETED | Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi’s Sarcoma |
| NCT06053749 | Not specified | ACTIVE_NOT_RECRUITING | An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden |
| NCT00002299 | Not specified | COMPLETED | The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS |
| NCT03808142 | Not specified | COMPLETED | PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).